Dendritic cell vaccines for prostate cancer
Article published in Urologia Polska 2007/60/2.

authors

Ivo Minarik ^1,2, Ivan Kawaciuk ¹, Jirina Bartunkova ²: ¹ Department Of Urology, 2nd Medical School, Charles University, Prague
² Department of Immunology, 2nd Medical School, Charles University, Prague

keywords

komórki dendrytyczne, immunoterapia, rak stercza, szczepionki

summary

Introduction. Metastatic disease represents the incurable stage for prostate cancer patients. New treatment modalities have been invented and tested. They will supplement or even replace contemporary treatment procedures. Dendritic cell based vaccines will play an important role in the treatment of prostate cancer patients.

The aim of the study. Summarize existing clinical studies utilizing dendritic cell vaccines in prostate cancer patients.

Material and methods. Analysis of published studies in medical literature and internet databases.

Conclusion. Dendritic cell vaccine based immunotherapy is a promising treatment alternative to prostate cancer patients, which needs further clinical evaluation. The future lies in the combination of dendritic cell vaccines and methods that lead to depletion of regulatory T-lymphocytes or change in tumor microenvironment.

references

Institute of Health Information and Statistics of the Czech Republic, Cancer Incidence 2002 in the Czech Republic, Prague: Health Statistics, 2005; Chapter 6, p.72
Janeway C,Travers T: Using the immune response to attack tumors. In Janeway C, Travers T. Immunobiology, 6th edn, 2004; Chapt 14, pp 630-642.
Dannull J, Diener P-A, Prikler L et al: Prostate Stem Cell Antigen Is a Promising Candidate for Immunotherapy of Advanced Prostate Cancer. Cancer Res 2000, 60, 5522-5528
Murphy GP, Tjoa BA, Simmons SJ et al: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999, 38, 73-78
Murphy GP, Tjoa BA, Simmons SJ et al: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999, 39, 54-59
Tjoa BA, Simmons SJ, Bowes VA et al: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998, 36, 39-44
Tjoa BA, Simmons SJ, Elgamal A et al: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999, 40, 125-129.
Waeckerle-Men Y, Allmen EU, von Moos R et al: Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate 2005, 64, 323-331.
Barrou B, Benoit G, Ouldkaci M et al: Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 2004, 53, 453-460.
Burch PA, Croghan GA, Gastineau DA et al: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004, 60, 197-204.
Schellhammer PF, Hershberg RM: Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World Journal of Urology 2005, 23, 47-49.
Valone FH, Small E, MacKenzie M et al: Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J 2001, 7 Suppl 2, S53-61.
Small EJ, Fratesi P, Reese DM et al: Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells. J Clin Oncol 2000, 18, 3894-3903.
Beinart G, Rini BI, Weinberg V, Small EJ: Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005, 4, 55-60
Heiser A, Maurice MA, Yancey DR et al: Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA. J Immunol 2001, 166, 2953-2960.
Heiser A, Coleman D, Dannull J et al: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109, 409-417.
Heiser A, Dahm P, Yancey DR, et al: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000, 164, 5508-5514.
Nair SK, Heiser A, Boczkowski D et al: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000, 6, 1011-1017.
Su Z, Dannull J, Yang BK et al: Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005, 174, 3798-3807.
Mu LJ, Kyte JA, Kvalheim G et al: Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005, 93, 749-756.
Kotera Y, Shimizu K, Mule JJ: Comparative Analysis of Necrotic and Apoptotic Tumor Cells As a Source of Antigen(s) in Dendritic Cell-based Immunization. Cancer Res 2001, 61, 8105-8109.
Pandha HS, John RJ, Hutchinson J et al: Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 2004, 94, 412-418
de Vries IJ, Lesterhuis WJ, Scharenborg NM et al: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003, 9, 5091-5100.
Eggert AA, Schreurs MW, Boerman OC et al: Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999, 59, 3340-3345.
Morse MA, Coleman RE, Akabani G et al: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999, 59, 56-58.
Fong L, Brockstedt D, Benike C et al: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001, 166, 4254-4259.
Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6, 345-352.
Dannull J, Su Z, Rizzieri D, et al: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115, 3623-3633.
von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6, 338-344.
Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6, 383-393.
Dudley ME, Wunderlich JR, Yang JC et al: Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. J Clin Oncol 2005, 23, 2346-2357.

correspondence